Opendata, web and dolomites

MS-INFINITE SIGNED

MASS SPECTROMETRY WITHOUT LIMITS: Pioneer MS equipment and Automated Sample Preparation unit to boost New Therapies Development

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MS-INFINITE project word cloud

Explore the words cloud of the MS-INFINITE project. It provides you a very rough idea of what is the project "MS-INFINITE" about.

1bn    automated    solution    kda    spectrometer    tof    instrumentation    analytes    trials    submitted    2015    combined    2022    maldi    medicine    saving    multicomponent    modern    molecular    weight    roi    prepare    commercialise    launch    patent    believe    efficiency    detection    industry    rely    analyte    18    preparation    size    times    molecules    spectrometers    clinical    innovation    jobs    experts    calibration    model    generating    selling    incompatible    plan    generate    life    quantification    regardless    nanomedicine    alzheimer    enter    viruses    ms    time    pioneering    infinite    nanoparticles    analytical    small    cancer    spectrometry    macromolecules    2020    primary    revenue    cures    heavy    determined    estimating    masses    pharmaceutical    company    too    asp    landscapes    despite    cumulative    reproducibly    standard    ineffective    100    comprising    biotechnology    tool    cryodetector    market    quantitative    quantitatively    drugs    profit    constituents    proteins    mass    conventional    therapies    meet    demands    11m    revenues    business    offers    failing    1st    specialists    detectors    arthritis    first    material    concentration   

Project "MS-INFINITE" data sheet

The following table provides information about the project.

Coordinator
METEXPERT SARL 

Organization address
address: RUE DU CHATEAU 10
city: NEUCHATEL
postcode: 2000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.metromol.ch/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    METEXPERT SARL CH (NEUCHATEL) coordinator 50˙000.00

Map

 Project objective

Modern medicine is evolving. Traditional drugs are small molecules with masses under 1 kDa. Emerging therapies increasingly rely on macromolecules 100 times this size: proteins, nanoparticles, viruses etc. Mass spectrometry is the primary tool for quantitative measurement in the pharmaceutical industry, generating revenues of €1.1Bn in 2015, but is failing to meet new demands. Conventional MS detectors become ineffective at 50 kDa making them incompatible with the emerging landscapes of biotechnology and nanomedicine. With a combined 70 years’ experience in analytical instrumentation, we plan to commercialise MS-INFINITE, our solution for large analyte mass quantification. MS-INFINITE is a multicomponent system, comprising a cryodetector MALDI-TOF mass spectrometer allowing 100% detection efficiency, regardless of molecular mass. MS-INFINITE also offers a pioneering calibration method, allowing concentration of specific constituents of large analytes to be quantitatively determined by MS for the first time (patent submitted). Through a unique business model, MS-INFINITE will generate revenue by selling an Automated Sample Preparation (ASP) unit to end-users, allowing non-specialists to reproducibly prepare clinical and pharmaceutical material for measurement. The market launch of MS-INFINITE’s ASP unit (2022) will bring the 1st revenues into our company, generating 18 new jobs, a cumulative profit of €11M, and a 5-years ROI of 5. Despite this, we believe our impact will be far more significant than company growth: MS-INFINITE has the potential to become the standard tool for quantification of analytes too heavy for existing mass spectrometers. With experts estimating that over 100 high molecular weight therapies will enter phase II or III clinical trials in 2020, our innovation will facilitate the development of pioneering advances in biotechnology and nanomedicine, allowing research to advance towards life-saving cures for cancer, Alzheimer’s and arthritis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MS-INFINITE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MS-INFINITE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

PLUTO (2019)

One-of-a-kind therapy for crossed eyes. Helping families to reduce emotional and financial burden of eye therapy.

Read More